Lightcalls.com
 

The Gonzalez Regimen for cancer L...

The Gonzalez Regimen for cancer

Living, a great quantity [i]or[/i] amount of less living longer, is a critical goal for clan diagnosed with pancreatic adenocarcinoma. The fifth-leading cause of cancer death in the U this form of cancer claimed near 27,800 lives in 1996, and is considered incurable. With an overall survival rate of les than single percent at 5 years after diagnosis, 80 percent of patients die within 1 year.

My colleague, Patty Andersen-Parrado, and I lately met with Nicholas J. Gonzalez, MD who has been able to propound a better scenario to patients who can tread on the heels of the "Gonzalez Regimen," a demanding program of diet, nutritional appendixs and detoxification.

In fact, the National Cancer Institute (NCI) is now supporting a major phase III clinical trial of the Gonzalez regimen face-to-face with the latest cancer unsalable article (gemcitabine) vs. pancreatic cancer at Columbia-Presbyterian Cancer Center in just discovered York City.

Here's a snapshot of Dr Gonzalez' "story:"



What l you to use pancreatic enzyme v cancer?

It was actually Scottish embryologist, John Beard, who first propos in 1906 that pancreatic enzyme portray by action the body's first defense against cancer. He died around 1923 and his work was largely forgotten until the 1960 when populace like William Donald Kelley revived the whole pancreatic enzyme idea as a cancer treatment.

My interest in Kelley's work eventually make knowned into my immunology fellowship thesis, which I wrote up in 1986 No individual could accept Kelley's remission of end-stage cancers. I was ridiculed. tribe said that this is crazy. Then we couldn't equal get it published. Around this time, Kelley clos his practice down, mainly dropp on the outside of the alternative treatment circles, and went back to his childhood to one's home in Kansas. I returned to of recent origin York in 1987 to have knowledge of to salvage the therapy.

I figured I'd behold patients, do the therapy, and hopefully achieve funding. My goal was always -- as was Kelley's originally -- to have this therapy mainstreamed. There was no point in keeping it our little unknown opening a series of clinics in Mexico. This was well adapted stuff, and this was what medicine should become. The simply way you can really do that is to learn it tested, and get nation to support it.

In July 7 1993 the NCI invited me down to at hand my best-case series using my regimen against pancreatic cancer. I instanted 25 cases. On the basis of the long-term survival of my patients in succession the regimen, the NCI commended I do a pilot studious mood As a result of the pilot investigation (Nutrition and Cancer, 33[2]:117-124, 1999) the NCI was convinced that a full-scale randomized research should be carried out.

What does your regimen consist of?

The reason we can't give solely one answer to this question is that everything we do is individualized, which is also the quintessence of Kelley's work and Roger Williams' work. We use 10 different diets, with 90 different variations, ranging from honest vegetarian, nuts and seeds to r meat sum of two units or three times a day. The postscripts are equally individualized.

in what way do your patients do?

The majority do well. For example, I had a patient who in 1988 was diagnosed at NYU with recurring metastatic lung cancer, with tumors in as well-as; not only-but also; not only-but; not alone-but lungs after surgery and radiation. They gave him 6 month to live. He's now alive, and well, 11 years later. The last time he suffer me X-ray him, a pair of years ago, he still had tumors in the one and the other lungs. Could I say that I "cured" him? Probably not. Could I say that I killed each cancer cell in his body? Probably not. Is he alive and well, and functioning normally? He's doing great.

Is there a certain quantity of message you don't feel has gotten out?

I think the single-most important thing you can do to debar cancer is to take (extra) pancreatic enzyme I think antioxidants are highly important, but ultimately, pancreatic enzyme are going to be shown to be the single-most important thing you can do to stop cancer.

Editor's note: tribe with pancreatic adenocarcinoma who are interested in finding without more about this study, may call the principal investigator, John Chabot, MD or Michelle Gabay, RN at: 212-305-9468 (Columbia Presbyterian Hospital).

COPYRIGHT 2000 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2000 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.